Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche receives draft NICE recommendation for MabThera

Roche receives draft NICE recommendation for MabThera

4th October 2013

Roche has been granted a draft recommendation from the UK's National Institute for Health and Care Excellence (NICE) for the use of MabThera in the treatment of a rare disease.

The rituximab-based therapy has been endorsed in draft guidance as an option for treating some adults with the autoimmune condition known as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

It has been recommended in combination with glucocorticoids as a means of inducing remission in this patient group, in cases where cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose.

The issuing of this draft guidance provides consultees with an opportunity to comment on information submitted by the manufacturer.

Professor Carole Longson, Health Technology Evaluation Centre director at NICE, said: "ANCA-associated vasculitis is a rare but serious autoimmune disease … NICE is therefore pleased to recommend rituximab as an option for some people with this condition in draft guidance."

This comes after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Roche's new breast cancer therapy Kadclya last month.ADNFCR-8000103-ID-801645806-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.